What is ICCC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.09B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ICCC?

P/E (TTM) is 113.04 and 52-week range is $4.52 to $12.10 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ICCC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ICCC?

The company profile lists revenue (TTM) near $30M, net income (TTM) near $776K, EPS (TTM) near $0.08 when available from the market-data feed. Figures are informational and may lag live markets.

Where is ImmuCell Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Portland, Maine, US, 9.1M shares outstanding, ISIN US4525253062 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

ImmuCell Corp

$ICCC

Health Care · Biotechnology

IR Run Scenarios

$9.80

+0.51%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 73 full-time employees. The firm is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. The company operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

Employees

Website

immucell.com/

IPO

1987-05-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)